Hypoxic pelvic perfusion with cisplatin and mitomycin C in multidisciplinary palliative treatment of patients with unresectable recurrent rectal cancer: a retrospective study.

CONCLUSIONS: Repeated HPP treatments with mitomycin C plus cisplatin, followed by cetuximab targeted-therapy, may represent a safe and efficacious palliative therapy in patients with unresectable recurrent rectal cancer, in progression following standard systemic chemo- and radio-therapy, and thus warrants confirmation in a larger phase III study. PMID: 31062943 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31062943?dopt=Abstract

Source: Minerva Chirurgica - May 9, 2019 Category: Surgery Tags: Minerva Chir Source Type: research